Rett Syndrome
Pipeline by Development Stage
Drug Modality Breakdown
Rare Diseases is a $21.9B market dominated by a single blockbuster (ELIQUIS), with moderate growth and high consolidation among top-tier pharma players.
Key Trends
- Market concentration: One product (ELIQUIS) represents 83% of market spending
- Complement inhibitors and enzyme replacement therapies gaining momentum
- Active pipeline with 1,790 trials, predominantly Phase 2-3 stage
Career Verdict
Yes, if you seek stability and commercial opportunity with major pharma; proceed cautiously if you want pipeline upside or innovation-driven roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 83% | LAUNCH | Stable | 15.0yr |
| 2 | XIFAXAN (rifaximin) | Bausch Health | $1.1B | 5% | LOE_APPROACHING | Declining | |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | PEAK | Stable | 10.2yr |
| 4 | TYVASO DPI (treprostinil) | United Therapeutics | $437M | 2% | PEAK | Stable | 15.7yr |
| 5 | STRENSIQ (asfotase alfa) | AstraZeneca | $259M | 1% | PEAK | Stable |
Drug Class Breakdown
Mature, patent-protected until 2041
Mixed—includes LOE-approaching products
Peak sales, LOE 2036
Stable, long patent protection
Emerging class, no LOE data available
Niche market, specialized patient populations
Career Outlook
StableThe rare disease market is stable but mature, with job growth concentrated in commercial and medical affairs rather than R&D innovation. Consolidation among top pharma (AstraZeneca, BMS, Amgen) limits opportunities for mid-tier companies, but specialist biotech firms show hiring momentum. Patent cliff risk for ELIQUIS (2041) will create restructuring opportunities and potential job flux in downstream years.
Breaking In
Target commercial or quality assurance roles at AstraZeneca, Capricor, or Amgen to build market knowledge; rare disease expertise is portable and valued across therapeutic areas.
For Experienced Professionals
Seek regulatory or medical affairs leadership roles where salary ceiling is highest ($243K-$257K); consider biotech firms like Insmed or Krystal for upside if pipeline approvals accelerate.
In-Demand Skills
Best For
Hiring Landscape
Rare disease hiring is concentrated in commercial roles (75 jobs at $215K avg) and medical affairs (16 jobs at $243K avg), reflecting a mature market's focus on market access and HCP engagement. Top hiring companies include AstraZeneca (38 jobs) and emerging biotech players like Capricor Therapeutics (30 jobs). Department salaries range from $114K-$257K, with regulatory affairs commanding premium compensation.
Top Hiring Companies
By Department
Commercial and regulatory roles offer strong salaries and growth; R&D hiring is minimal (10%), reflecting a consolidation and maturity phase in the market.
On Market (3)
Approved therapies currently available
Competitive Landscape
15 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 31 trials with date data
Clinical Trials (31)
Total enrollment: 6,665 patients across 31 trials
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome
A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)
Open-Label Extension Study of Trofinetide for Rett Syndrome
A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome
To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome
An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms
Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Patients
Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome.
Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin
A Safety Study of NNZ-2566 in Pediatric Rett Syndrome
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)
Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT)
Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome
Technology-supported Motor Rehabilitation for People With Rett Syndrome
The Diagnostic Experience of Male Rett Syndrome
Rett Syndrome Registry
Biobanking of Rett Syndrome and Related Disorders
Development of a Behavioral Outcome Measure for Rett Syndrome (RettBe)
Natural History of Rett Syndrome & Related Disorders
Genetic and Physical Characteristics of Rett Syndrome
Study of Cardiac and Paroxysmal Abnormalities in Rett Syndrome
Study of the Pathogenesis of Rett Syndrome
Nutritional Aspects of Rett Syndrome
Related Jobs in Rare Diseases
Ingénieur Industrialisation Expérimenté - F/H
Director, Medical Writing
Senior Manager, International Accounting
LIMS System & Data Specialist II
Regional Business Director, Rare Disease - Northeast
Director, Quality Assurance & Quality Systems
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.